

Dubravka CvejiÄ

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/847946/publications.pdf>

Version: 2024-02-01

15
papers

244
citations

840776

11
h-index

1058476

14
g-index

15
all docs

15
docs citations

15
times ranked

350
citing authors

#	ARTICLE	IF	CITATIONS
1	Coexistence of BRAFV600E mutation and EGFR overexpression is highly associated with adverse clinicopathological features of papillary thyroid carcinoma. Archives of Biological Sciences, 2020, 72, 37-44.	0.5	0
2	MMP-9-1562 C/T single nucleotide polymorphism associates with increased MMP-9 level and activity during papillary thyroid carcinoma progression. Pathology, 2019, 51, 55-61.	0.6	15
3	Overexpression of epidermal growth factor receptor and its downstream effector, focal adhesion kinase, correlates with papillary thyroid carcinoma progression. International Journal of Experimental Pathology, 2018, 99, 87-94.	1.3	15
4	High expression and localization of β -catenin and epidermal growth factor receptor identify high risk papillary thyroid carcinoma patients. Experimental and Molecular Pathology, 2018, 105, 181-189.	2.1	6
5	Concomitant high expression of survivin and vascular endothelial growth factor-C is strongly associated with metastatic status of lymph nodes in papillary thyroid carcinoma. Journal of Cancer Research and Therapeutics, 2018, 14, S114-S119.	0.9	14
6	Inverse expression of caveolin-1 and EGFR in thyroid cancer patients. Human Pathology, 2017, 61, 164-172.	2.0	15
7	Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation. Apmis, 2016, 124, 271-277.	2.0	14
8	Defining the value of CD56, CK19, Galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature. Diagnostic Pathology, 2015, 10, 196.	2.0	44
9	Malignant risk stratification of thyroid FNA specimens with indeterminate cytology based on molecular testing. Cancer Cytopathology, 2015, 123, 471-479.	2.4	26
10	Changes in the expression pattern of apoptotic molecules (galectin-3, Bcl-2, Bax, survivin) during progression of thyroid malignancy and their clinical significance. Wiener Klinische Wochenschrift, 2015, 127, 337-344.	1.9	18
11	Enhanced activation of matrix metalloproteinase-9 correlates with the degree of papillary thyroid carcinoma infiltration. Croatian Medical Journal, 2014, 55, 128-137.	0.7	31
12	Evaluation of survivin expression and its prognostic value in papillary thyroid carcinoma. Pathology Research and Practice, 2014, 210, 30-34.	2.3	13
13	Caveolin-1 Expression in Thyroid Neoplasia Spectrum: Comparison of Two Commercial Antibodies. Disease Markers, 2012, 33, 321-331.	1.3	2
14	Apoptosis and proliferation related molecules (Bcl-2, Bax, p53, PCNA) in papillary microcarcinoma versus papillary carcinoma of the thyroid. Pathology, 2008, 40, 475-480.	0.6	21
15	Differential expression of Galectin-3 in papillary projections of malignant and non-malignant hyperplastic thyroid lesions. Acta Chirurgica Iugoslavica, 2003, 50, 67-70.	0.0	10